Author

Dirk Tummes

Observed names: D. Tummes, Tummes, Dirk

Observed institutions: University of Freiburg, Roche Pharma AG (Germany), University Cancer Center Hamburg, Asklepios Klinikum Harburg, Klinikum Fulda, Asklepios, Martin Luther University Halle-Wittenberg

OpenAlex ID: A5086889296

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

2013 · S. Kubicka, R. Greil, et al. · Annals of Oncology · 103

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

2017 · Julia Quidde, Laura Denne, et al. · Oncology Research and Treatment · 7

Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study.

2012 · Ralf Hofheinz, Wilfried Grothe, et al. · Journal of Clinical Oncology · 5

Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany

2009 · D. Arnold, M. Kindler, et al. · Journal of Clinical Oncology · 3

SORAVE: Sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC—A phase I study.

2013 · Lucia Nogova, Christian Mattonet, et al. · Journal of Clinical Oncology · 2

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment · 1

Nebenwirkungen antihormoneller Therapie – Bewältigungsstrategien

2021 · Dirk Tummes, Volker Perst · Springer eBooks

Meetings and Conferences

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

Society Bulletins

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

Editorial Board / Contents / Imprint

2017 · De Zeng, Danxia Lin, et al. · Oncology Research and Treatment

Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study.

2012 · Dirk Arnold, Wilfried Grothe, et al. · Journal of Clinical Oncology

Works count: 16

Citation count: 187

H-index: 4

I10-index: 2